Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) PT at $9.33

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have been given an average recommendation of “Hold” by the ten research firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $9.33.

A number of research analysts recently issued reports on the company. Royal Bank of Canada reiterated a “sector perform” rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th. HC Wainwright reiterated a “neutral” rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th.

Hedge Funds Weigh In On Fulcrum Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. National Bank of Canada FI lifted its stake in Fulcrum Therapeutics by 869.6% in the 2nd quarter. National Bank of Canada FI now owns 4,460 shares of the company’s stock worth $28,000 after purchasing an additional 4,000 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Fulcrum Therapeutics by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company’s stock worth $43,000 after purchasing an additional 4,701 shares during the last quarter. Walleye Capital LLC purchased a new stake in shares of Fulcrum Therapeutics in the third quarter worth about $59,000. Intech Investment Management LLC bought a new position in Fulcrum Therapeutics during the third quarter valued at approximately $62,000. Finally, Profund Advisors LLC purchased a new position in Fulcrum Therapeutics during the 2nd quarter valued at approximately $68,000. Institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Stock Performance

NASDAQ:FULC opened at $4.17 on Thursday. The stock has a 50-day simple moving average of $4.01 and a two-hundred day simple moving average of $5.51. The firm has a market capitalization of $224.93 million, a PE ratio of -13.45 and a beta of 2.06. Fulcrum Therapeutics has a 52-week low of $2.86 and a 52-week high of $13.70.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.